Designing the ideal selective estrogen receptor modulator-an achievable goal?

Menopause

Volumn 16, Issue 3, 2009, Pages 609-615

  Taylor, Hugh S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer risk.; Estrogens; Osteoporosis; Postmenopausal; Selective estrogen receptor modulator (SERM)

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; CLOMIFENE; CONJUGATED ESTROGEN; LASOFOXIFENE; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CANCER INVASION; CHEMICAL STRUCTURE; DEEP VEIN THROMBOSIS; DRUG FATALITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FRACTURE; HOT FLUSH; HUMAN; MASTALGIA; MENOPAUSAL SYNDROME; METASTASIS; OVARY INSUFFICIENCY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; STROKE; VAGINA ATROPHY; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; FEMALE; HUMANS; OSTEOPOROSIS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 67649574704     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181906fa3     Document Type: Review

References (72)

1. Riggs BL, Hartmann LC. Selective estrogen receptor modulators V mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629.
2. Kian TM, Rogatsky I, Tzagarakis-Foster C, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 2004;15:1262-1272.
3. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181-210.
4. Henke BR, Heyer D. Recent advances in estrogen receptor modulators. Curr Opin Drug Discov Devel 2005;8:437-448.
5. Ullrich JW, Miller CP. Estrogen receptor modulator review. Exp Opin Ther Patents 2006;16:559-572.
6. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005; 591:247-263.
7. Barkhem T, Nilsson S, Gustafsson JA. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 2004;4:19-28.
8. Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int 2007;13:27-34.
9. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25: 45-71.
10. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-213.
11. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 2001;93:1449-1457.
12. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
13. McDonnell DP. The molecular pharmacology of SERMs. Trends Endocrinol Metab 1999;10:301-311.
14. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004;94:256-266.
15. American College of Obstetricians and Gynecologists. ACOG committee opinion. Tamoxifen and endometrial cancer. Number 169, February 1996. Committee on Gynecologic Practice. Int J Gynaecol Obstet 1996; 53:197-199.
16. O'Regan RM, Jordan VC. Tamoxifen to raloxifene and beyond. Semin Oncol 2001;28:260-273.
17. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
18. Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular effects of selective estrogen receptor modulators. Ann N Y Acad Sci 2006;1092:374-384.
19. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-1406.
20. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294.
21. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
22. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-1847.
23. Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet 2000;355:848-849.
24. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-1647.
25. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-645.
26. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
27. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617.
28. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-532.
29. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-1524.
30. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
31. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137.
32. Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-517.
33. Glusman JE, Huster WJ, Paul S. Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women. Prim Care Update Ob Gyns 1998;5:166.
34. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-565.
35. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-73.
36. FleischerAC,Wheeler JE, Yeh IT, Kravitz B, Jensen C, MacDonald B. Sonographic assessment of the endometrium in osteopenic post-menopausal women treated with idoxifene. J Ultrasound Med 1999; 18:503-512.
37. Smith Kline Beecham drops idoxifene for osteoporosis. SCRIP 1999; 2431:21.
38. Warming L, Christoffersen C, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. Maturitas 2003;44:189-199.
39. Novo Nordisk drops levormeloxifene. SCRIP 1998;2374:18.
40. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-326.
41. Ronkin S, Clarke L. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion [Abstract SU437]. J Bone Miner Res 2001;16(suppl 1):S413.
42. Boudes P, Ronkin S, Korner P, Baracat E, Constantine G. Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain [Abstract OC39]. Osteoporos Int 2003;14(suppl 7):S14.
43. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404.
44. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study [published erratum appears in J Bone Miner Res 2008;23:972]. J Bone Miner Res 2008;23:525-535.
45. Silverman S, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-1934.
46. Pinkerton JV, Utian WH, Archer DF, Levine A, Chines AA, Constantine G. Endometrial and ovarian safety of bazedoxifene (BZA) in the prevention of postmenopausal osteoporosis [Abstract P-407]. Fertil Steril 2007;88(suppl 1):S241-S242.
47. Archer DF, Utian W, Pinkerton JV, et al. Endometrial safety of bazedoxifene, a new selective estrogen receptor modulator (SERM), in the treatment of postmenopausal (PM) osteoporosis [Abstract P-14]. Menopause 2007;14:1091.
48. Pickar JH. Tissue selective estrogen complex: a new paradigm for menopausal therapy. Menopausal Med 2008;16:S10-S13.
49. Lewiecki EM. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 2007;16:1663-1672.
50. McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006;13:377-386.
51. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (LASO), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA). Menopause 2005;12:238.
52. Gass M, Portman D, Bachmann G, Moffett A, Symons J. Clinical signs of vaginal atrophy are improved by the SERM, lasofoxifene [Abstract P-68]. Menopause 2004;11:670.
53. Bachmann G, Gass M, Moffett A, Portman D, Symons J. Lasofoxifene improves symptoms associated with vaginal atrophy [Abstract P-63]. Menopause 2004;11:669.
54. Postmenopausal Evaluation and Risk-Reduction With Lasofoxifene (PEARL). ClinicalTrials.gov Identifier: NCT00141323. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00141323?term=lasofoxifene&rank=1. Accessed May 14, 2008.
55. CORAL: Comparison of Raloxifene and Lasofoxifene - a randomized, blinded study of these drugs and placebo on bone loss. ClinicalTrials. gov Identifier: NCT00163137. Available at: http://www.clinicaltrials.gov/ct/show/NCT00163137? order=3. Accessed April 24, 2008.
56. A clinical study to evaluate ospemifene in the treatment of vulvar and vaginal atrophy in postmenopausal women. ClinicalTrials.gov Identifier: NCT00276094. Available at: http://www.clinicaltrials.gov/ct/show/NCT00276094? order=1. Accessed April 24, 2008.
57. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005;12:202-209.
58. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43:207-214.
59. RutanenEM,Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003;10:433-439.
60. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24:314-318.
61. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18:152-158.
62. Munster PN. Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs 2006;15:317-326.
63. Fabian CJ, Kimler BF, Anderson J, et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 2004; 10:5403-5417.
64. Munster PN, Buzdar A, Dhingra K, et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. J Clin Oncol 2001;19:2002-2009.
65. Baselga J, Llombart-Cussac A, Bellet M, et al. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 2003;14:1383-1390.
66. McMeekin DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003;90: 64-69.
67. Buzdar A, O'Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21: 1007-1014.
68. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 2007;25: 4967-4973.
69. Study comparing arzoxifene with raloxifene in women after menopause with osteoporosis. ClinicalTrials.gov Identifier: NCT00383422. Available at: http://www.clinicaltrials.gov/ct/show/NCT00383422?order=5. Accessed April 24, 2008.
70. Ning M, Zhou C, Weng J, et al. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134). Br J Pharmacol 2007;150:19-28.
71. Wallace OB, Lauwers KS, Dodge JA, et al. A selective estrogen receptor modulator for the treatment of hot flushes. J Med Chem 2006; 49:843-846.
72. Hattersley G, Paquin DG, Ho S, et al. RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms. Abstract presented at: the 89th Annual Meeting of the Endocrine Society; June 2-5, 2007; Toronto, Ontario, Canada. Abstract P1-415.